Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne Trial
13. März 2025 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, March 13, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) ("Kane Biotech" or "Kane") announces today that it has received approval from the Internal Review...
Kane Biotech Announces Canadian Distribution Agreement With Best Buy Medical for revyve™ Antimicrobial Wound Gel
11. März 2025 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, March 11, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (“Kane Biotech”) announces that it has concluded a three-year distribution agreement with Best Buy...
Kane Biotech Announces Second and Final Closing of Private Placement Offering
19. Februar 2025 08:30 ET
|
Kane Biotech Inc.
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the...
Kane to Host Investor Webinar – What Kane has in Store for 2025 Including the Acquisition of FB Dermatology
21. Januar 2025 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane”) announces that it will be hosting a webinar on Thursday, January 23, 2025 at 4:15pm Eastern...
Kane Biotech Announces First Closing of Private Placement Offering and Extension of Private Placement Offering
20. Januar 2025 08:30 ET
|
Kane Biotech Inc.
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”,...
Kane Biotech Announces $3,000,000 Private Placement Offering
03. Dezember 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it intends to undertake a non-brokered...
Kane Biotech Announces Third Quarter 2024 Financial Results
28. November 2024 16:15 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announces its third quarter 2024 financial results. ...
Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel
27. November 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company”, “Kane Biotech” or “Kane”) announces today that BioStem Technologies Inc....
Kane Biotech to Release Third Quarter 2024 Financial Results on November 28, 2024
21. November 2024 16:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”) will release its third quarter 2024 financial results after market close on...
Kane Biotech Announces Health Canada Approval of revyve™ Antimicrobial Wound Gel
14. November 2024 13:10 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has received Health Canada approval of its...